|Assessment Status||Assessment process complete|
|Drug||House Dust Mite Extract|
|Indication||For the treatment of adult patients (18-65 years) diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.|
|Rapid review commissioned||12/03/2020|
|Rapid review completed||30/04/2020|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract compared with the current standard of care.|
The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.